The analyst was referring to Amarin (AMRN). Check his website.
This company is like Dendreon, oh wait, Dendreon actually had an approved cancer product that generated 200-400mil per year.
Neuvax was bought from the scrap heap
Abstral is the only product GALE will ever have, and with quaterly sales of about $2-$4 million, bankruptcy will only be a few years away.
JKOKAO is spot on above wherea Michael's numbers are highly dillusional.
I'm long holding XX,XXX amount of shares, but being realistic you will never see $51.81 again.
Do you know how many times GERN had diluted and issued shares since then?
Let's assume they were $52 with 20/million shares outstanding.
Now we have 100/plus million shares outstanding, 5 fives the amount of shares.
Take your $52 price and now divide by 5, today's equivalent price would be about $10.40 a share which would be the equivalent of $52/back then with 20/million shares outstanding.
I'm holding like 25k shares but tomorrow small baby bios get pounced on the ACAD fraud news.